A Place for Hope

Historically, melanoma brain metastases have been associated with a very poor prognosis.  A recent study showed that the BRAF inhibitor dabrafenib can cause BRAF mutant melanoma brain metastases to regress.  Additional studies suggest that adding focused radiation or the MEK inhibitor trametinib to dabrafenib can help to eradicate melanoma cells and, potentially, to keep melanoma patients healthy for longer.  We are currently conducting a clinical trial that is unique to UCSF combining dabrafenib, trametinib, and focused radiation (stereotactic radiosurgery) to treat patients with BRAF mutant melanoma that has metastasized to the brain. 

Key Inclusion / Exclusion Criteria: 
  • BRAFV600E/K melanoma
  • Prior neurosurgery or radiation therapy is permitted
  • 1-4 new or untreated brain lesions
  • No prior treatment with a BRAF or MEK inhibitor (e. g. vemurafenib, dabrafenib, trametinib)
  • No untreated lesion over 3 cm in maximum diameter
  • No leptomeningeal involvement (cancer in the lining of the brain)

Contact:  Dr. Alain Algazi, (415) 353-7552, alain.algazi@ucsf.edu

Clinicaltrials.gov link: http://www.clinicaltrials.gov/ct2/show/NCT01721603